Akamis Bio welcomes Andrew Hirsch to its Board of Directors
– USA, MA – Akamis Bio, a clinical-stage oncology company using a proprietary Tumor-Specific Immuno-Gene Therapy platform to deliver novel immunotherapeutic payloads to solid tumors, announced the appointment of Andrew Hirsch to its Board of Directors.…